During the corresponding time, Marinus Pharmaceuticals Inc recorded a revenue increase by 16.39 % year on year, sequentially revenue grew by 6.02 %. While revenue at the Marinus Pharmaceuticals Inc 's corporate clients
Marinus Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company operates in the U.S. market, focusing on reimbursement from commercial payers and government payers, primarily Medicaid, for the target population of CDD. Approximately 50% of the CDD patient population receives coverage through Fee-for-Service or Managed Medicaid, while the other 50% is covered by commercial payers influenced by major pharmacy benefit managers (PBMs). The prescribing and fulfillment process for ZTALMY is managed through the ZTALMY One™ patient support program. Orsini Pharmaceutical Services, LLC provides specialty pharmacy services, including patient enrollment, benefit verification, prior authorization support, patient education, drug counseling, dispensing, and shipment coordination. ASD Specialty Healthcare, LLC serves as a specialty distributor for institutional inpatient pharmacies, U.S. governmental customers such as the Department of Veterans Affairs and Department of Defense sites, and Kaiser Permanente facilities.
Marinus Pharmaceuticals, Inc. a trailblazer in the development of innovative treatments for seizure disorders, has made significant strides recently, showcasing its commitment to advancing therapies for patients in need. Three pivotal announcements provide a comprehensive insight into the company’s evolving landscape. 1. Prominent Presentations at Neurocritical Care Society Annual Meeting Marinus Pharmaceuticals is slated to present new data at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, scheduled to take place from October 14-17 in San Diego, California. The focus of these presentations centers on additional findings from the Phase 3 RAISE trial concerning refractory status epilept...
Marinus Pharmaceuticals, a leading pharmaceutical company focused on developing innovative therapies for seizure disorders, recently announced the approval of ganaxolone oral suspension by the China National Medical Products Administration (NMPA). This landmark approval marks a significant breakthrough in the treatment of epileptic seizures associated with CDKL5 deficiency disorder (CDD). The collaborative efforts of Marinus Pharmaceuticals and Tenacia Biotechnology have paved the way for patients aged two years and above to benefit from this groundbreaking treatment.Unmet Medical Need:CDKL5 deficiency disorder, a rare and severe genetic disorder, affects brain development and causes early-onset seizures. Pr...
Marinus Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company operates in the U.S. market, focusing on reimbursement from commercial payers and government payers, primarily Medicaid, for the target population of CDD. Approximately 50% of the CDD patient population receives coverage through Fee-for-Service or Managed Medicaid, while the other 50% is covered by commercial payers influenced by major pharmacy benefit managers (PBMs). The prescribing and fulfillment process for ZTALMY is managed through the ZTALMY One™ patient support program. Orsini Pharmaceutical Services, LLC provides specialty pharmacy services, including patient enrollment, benefit verification, prior authorization support, patient education, drug counseling, dispensing, and shipment coordination. ASD Specialty Healthcare, LLC serves as a specialty distributor for institutional inpatient pharmacies, U.S. governmental customers such as the Department of Veterans Affairs and Department of Defense sites, and Kaiser Permanente facilities.
Sources:
Marinus Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Marinus Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Marinus Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
